Sciwind Biosciences seeks additional partners for obesity drug ecnoglutide after deals with Pfizer and Verdiva Bio
read at Endpoints ↗DealPositive
Sciwind Biosciences, a Chinese biotech, has licensed its GLP-1 obesity candidate ecnoglutide to two Western companies.
The first agreement grants Pfizer rights to develop and commercialize the drug, while a second license gives Verdiva Bio similar rights.
Sciwind said it is still looking for additional partners to cover the remaining rights and will continue discussions with potential collaborators.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sciwind has two Western partners for its obesity drug, but is open to more”
read at Endpoints ↗91 words · retrieved Jun 12
comments(0)
5-min edit window · permanent after that